AT-001

Unassigned

New Medicines

Diabetic cardiomyopathy

Information

New molecular entity
Applied Therapeutics
Applied Therapeutics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Selective aldose reductase inhibitor
Diabetic cardiomyopathy affects 17 – 24 percent of those with both types of diabetes and is a rapidly progressing degenerative disorder of the heart. It affects approximately 77 million patients worldwide [1].
Diabetic cardiomyopathy
Oral